USF Gene Therapy Could Treat Dog Dementia

When Kate Heath's 12-year-old rescue pug Ivy started staring blankly at walls and wandering into corners, veterinarians had no real treatment to offer. Heath could only watch helplessly as dementia stole away her once-affectionate companion.

Now, researchers at USF Health are working to change that heartbreaking reality for dog owners everywhere. Aurelie Joly, a research associate at the Morsani College of Medicine, is advancing a gene therapy that could treat canine cognitive decline at its source rather than just masking symptoms.

The innovative treatment uses a modified, harmless virus to deliver genetic instructions directly into brain cells. Those cells then become tiny factories, continuously producing a protective protein that shields the brain from damage caused by aging.

"It's like a mini factory inside the body that continuously produces a beneficial protein after a single treatment," Joly explained. The protein reduces oxidative stress and protects cells from damage, functioning almost like sunscreen for brain cells.

The research is particularly promising because dogs develop cognitive decline naturally as they age, just like humans with Alzheimer's. That makes them better models for understanding the disease than traditional lab animals, potentially opening doors for human treatments down the road.

Joly co-founded Blue Zone Therapeutics with colleagues to move this technology from laboratory research toward real-world veterinary applications. Funding from the National Science Foundation and the Florida High Tech Corridor's Early-Stage Innovation Fund is helping advance the therapy toward veterinary studies and eventual commercialization.

Why This Inspires

For Heath, who connected with Joly through Embarc Collective, the research represents hope she wished she'd had for Ivy. After consulting multiple veterinarians, she heard the same devastating message repeatedly: dog dementia is real, but there's nothing anyone can do about it.

"If I thought there was anything I could do to avoid or arrest her decline, I would have done it," Heath said. Instead, she made one of the hardest decisions of her life. Ivy passed away in February 2024.

Heath's experience isn't rare. Millions of dog owners face the same agonizing situation as their beloved pets age, watching cognitive decline steal away the companions they love with no treatment options available.

Joly anticipates veterinary development could move faster than human drug development since regulatory pathways are different. That means aging pets and their devoted owners might not have to wait decades for help.

The therapy has already shown promise in previous animal studies. Now researchers are working to scale up production and develop new ways to measure its effectiveness specifically in dogs before moving to veterinary trials.

For dog owners everywhere facing what Heath faced, this research offers something that's been missing: genuine hope that cognitive decline doesn't have to be inevitable.